SEC Form 4 · accession 0001209191-16-156173
Aclaris Therapeutics, Inc. · ACRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stuart Shanler
Officer — Chief Scientific Officer
Period of report
Dec 18, 2016
Accepted (ET)
Dec 20, 2016 · 6:49 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001557746
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 18, 2016 | M | 1,450 | — | A | 262,319 | D | |
| Common Stock | Dec 18, 2016 | F | 441 | $31.25 | D | 261,878 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F3 | — | Dec 18, 2016 | M | 1,450 | D | — | — | Common Stock | 1,450 | 4,350 | D |
Explanation of responses
- F1Restricted stock units convert into common stock on a one-for-one basis.
- F2The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4.
- F3On December 18, 2015, the reporting person was granted 5,800 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.